BTN3A1

BTN3A1 is a transmembrane immunoreceptor that functions as an intracellular phosphoantigen sensor to activate Vγ9Vδ2 T cells, while also modulating αβ T cell responses and innate immune signaling. Its intracellular B30.2 domain directly binds pyrophosphate metabolites (HMBPP with ~1 μM affinity, IPP with ~627 μM affinity), and only bona fide phosphoantigens induce a specific conformational change that propagates through the B30.2 domain to disrupt a preexisting homodimer interface, ultimately triggering heterodimerization with BTN2A1 via HMBPP-bridged B30.2 domain interactions (PMID:25637025, PMID:28807997, PMID:28862425, PMID:37171180). Beyond γδ T cell activation, BTN3A1 inhibits αβ TCR signaling by retaining N-glycosylated CD45 at the immune synapse, constitutively associates with TBK1 to promote dynein-dependent perinuclear redistribution and IRF3-mediated type I interferon production upon nucleic acid sensing, and interacts with periplakin through a cytoplasmic di-leucine motif required for γδ T cell responses (PMID:32820120, PMID:27911820, PMID:25637025). BTN3A1 also promotes radioresistance in esophageal squamous cell carcinoma through ULK1 interaction and autophagy activation downstream of HIF-1α-driven transcription (PMID:36418890).

1. 2011 Medium

   Establishing that BTN3A1, uniquely among CD277 isoforms, has co-stimulatory activity on αβ T cells dependent on its B30.2 domain resolved why CD277 engagement has different effects on T cells versus NK cells.

   Evidence Isoform-selective antibody engagement with cytokine/proliferation readouts in T and NK cells

   PMID:21918970

   Open questions at the time

   • Co-stimulatory mechanism not defined at molecular level
   • No ligand for extracellular domain identified
2. 2012 High

   Identifying BTN3A1 as the specific isoform required for phosphoantigen-induced Vγ9Vδ2 T cell activation, and showing that intracellular pAg accumulation reduces BTN3A1 membrane mobility, established the inside-out sensing paradigm.

   Evidence FRAP, CD277 knockdown, domain-shuffling, and agonist/antagonist antibody assays; crystal structures of BTN3A homodimers and antibody-binding epitopes

   PMID:22767497 PMID:22846996

   Open questions at the time

   • Direct pAg–B30.2 binding not yet demonstrated
   • Identity of additional chromosome 6 genes required for pAg response unknown
3. 2014 Medium

   Genetic complementation showed BTN3A1 alone suffices for agonist antibody-mediated activation but pAg-mediated activation requires additional human chromosome 6 gene(s), separating antibody-triggered from pAg-triggered pathways.

   Evidence BTN3A1 transduction versus full chromosome 6 transfer in CHO cells with γδ T cell activation readout

   PMID:24890657

   Open questions at the time

   • Identity of the additional chromosome 6 factor(s) not determined at this point
   • Mechanism of cooperation unknown
4. 2015 High

   Direct measurement of pAg binding to the B30.2 domain (HMBPP ~1 μM, IPP ~627 μM) and identification of periplakin as a cytoplasmic interactor via a di-leucine motif established the molecular basis of intracellular sensing and linked cytoskeletal coupling to γδ T cell activation.

   Evidence In vitro binding assays, yeast two-hybrid, knockdown/re-expression with coculture functional assays

   PMID:25637025

   Open questions at the time

   • How periplakin interaction transmits signal to the extracellular face unknown
   • Structural basis of pAg binding not yet resolved
5. 2016 High

   Discovery that BTN3A1 constitutively associates with TBK1 and mediates its dynein-dependent perinuclear redistribution upon nucleic acid sensing to drive IRF3 phosphorylation and IFN-β production revealed a second, innate-immune signaling function independent of γδ T cell activation.

   Evidence Reciprocal co-IP, siRNA knockdown, subcellular fractionation/imaging, IFN-β reporter assays

   PMID:27911820

   Open questions at the time

   • Whether TBK1 and pAg-sensing functions are coordinated or independent is unclear
   • MAP4 regulatory mechanism not fully defined
6. 2016 Medium

   Demonstration that HMBPP must be internalized for BTN3A1-dependent target cell lysis, bypassed by a cell-permeable prodrug, strengthened the inside-out model of pAg sensing.

   Evidence Cytotoxicity assays with BTN3A1 disruption, temperature-dependent uptake, prodrug comparison

   PMID:27271567

   Open questions at the time

   • Identity and regulation of the pAg uptake transporter not established
7. 2017 High

   NMR and crystallography revealed that pAg binding induces a global conformational change in the B30.2 domain distinct from nonspecific charge-driven binding, disrupting the intracellular dimer interface and propagating to extracellular domains, explaining how intracellular sensing triggers surface presentation.

   Evidence NMR chemical shift perturbation, X-ray crystallography, molecular dynamics, juxtamembrane mutagenesis with T cell activation assays

   PMID:28461569 PMID:28807997 PMID:28862425

   Open questions at the time

   • Structural linkage from B30.2 rearrangement through transmembrane to extracellular domains not atomically resolved
   • Role of juxtamembrane dimerization interface incompletely defined
8. 2020 High

   BTN3A1 was shown to inhibit αβ T cell activation by preventing CD45 exclusion from the immune synapse, while anti-CD277 antibodies restore αβ effector function and elicit BTN2A1-dependent γδ cytotoxicity, unifying its dual role as immunosuppressive for αβ and immunoactivating for γδ T cells in cancer.

   Evidence Genetic KO/KD, immune synapse imaging, in vitro and in vivo tumor models, antibody functional assays

   PMID:32820120

   Open questions at the time

   • Structural mechanism of CD45 retention at the synapse not defined
   • Relative importance of αβ inhibition versus γδ activation in tumor immunity unclear
9. 2022 Medium

   Identification of ULK1 as a BTN3A1 interactor that promotes autophagy-mediated radioresistance downstream of HIF-1α-driven BTN3A1 transcription extended BTN3A1 function to cancer cell-intrinsic stress responses.

   Evidence Co-IP/mass spectrometry, ChIP, luciferase reporter, KO/OE functional assays in esophageal squamous cell carcinoma

   PMID:36418890

   Open questions at the time

   • Mechanism of ULK1 phosphorylation by BTN3A1 interaction not defined
   • Generalizability to other cancer types not established
   • Relationship to immune functions of BTN3A1 unexplored
10. 2023 High

    Biophysical demonstration that HMBPP bridges BTN3A1 and BTN2A1 B30.2 domains, and that BTN2A1 B30.2 homodimerization is prerequisite for this interaction, resolved the molecular logic of the BTN3A1–BTN2A1 partnership required for γδ T cell activation.

    Evidence 31P-NMR, solution NMR, SEC, ITC, site-directed mutagenesis, T cell IFN-γ ELISA

    PMID:37171180

    Open questions at the time

    • Full-length heterodimer structure not resolved
    • Stoichiometry at the cell surface unknown
11. 2025 Medium

    19F NMR mapping of specific B30.2 residues (W421, T449, T506) undergoing conformational changes upon HMBPP and BTN2A1 binding localized the allosteric propagation pathway within the B30.2 domain, while juxtamembrane residues were unaffected.

    Evidence 19F solution NMR with site-directed mutagenesis and binding affinity measurements

    PMID:40079188

    Open questions at the time

    • How conformational change in B30.2 propagates through transmembrane domain to ectodomains remains unresolved
    • Dynamic measurements limited to selected point mutants

• The complete structural mechanism by which intracellular pAg-induced B30.2 conformational changes propagate through the transmembrane region to reorganize BTN3A1 ectodomains for TCR engagement remains unresolved at atomic resolution in a full-length membrane-embedded context.
• No full-length BTN3A1 structure in a lipid membrane environment
• Mechanism of juxtamembrane phosphorylation and its regulatory role not established in peer-reviewed literature
• Identity and regulation of the pAg uptake transporter still unknown